Accuray Incorporated (ARAY)vsEdwards Lifesciences Corp (EW)
ARAY
Accuray Incorporated
$0.26
-6.46%
HEALTHCARE · Cap: $31.48M
EW
Edwards Lifesciences Corp
$90.78
-1.70%
HEALTHCARE · Cap: $51.66B
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 1371% more annual revenue ($6.30B vs $428.57M). EW leads profitability with a 17.4% profit margin vs -10.8%. EW appears more attractively valued with a PEG of 2.15. EW earns a higher WallStSmart Score of 59/100 (C).
ARAY
Hold35
out of 100
Grade: F
EW
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ARAY.
Margin of Safety
+68.6%
Fair Value
$252.36
Current Price
$90.78
$161.58 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Strong operational efficiency at 31.2%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
16.7% revenue growth
Areas to Watch
Smaller company, higher risk/reward
Expensive relative to growth rate
ROE of -110.6% — below average capital efficiency
Revenue declined 7.4%
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : ARAY
The strongest argument for ARAY centers on Price/Book.
Bull Case : EW
The strongest argument for EW centers on Operating Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 17.4% and operating margin at 31.2%. Revenue growth of 16.7% demonstrates continued momentum.
Bear Case : ARAY
The primary concerns for ARAY are Market Cap, PEG Ratio, Return on Equity. Debt-to-equity of 4.37 is elevated, increasing financial risk.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 48.5x leaves little room for execution misses.
Key Dynamics to Monitor
ARAY profiles as a turnaround stock while EW is a growth play — different risk/reward profiles.
ARAY carries more volatility with a beta of 1.35 — expect wider price swings.
EW is growing revenue faster at 16.7% — sustainability is the question.
ARAY generates stronger free cash flow (-7M), providing more financial flexibility.
Bottom Line
EW scores higher overall (59/100 vs 35/100), backed by strong 17.4% margins and 16.7% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Accuray Incorporated
HEALTHCARE · MEDICAL DEVICES · USA
Accuray Incorporated designs, develops and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body in the Americas, Europe, the Middle East, India, Japan, Africa and the rest of the Asia Pacific region. The company is headquartered in Sunnyvale, California.
Visit Website →Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?